“My excitement stems from the fact that CAB-LA, administered every two months, has been shown to be more effective than oral PrEP in reducing new HIV infections,” said Dr. Antonio Flores, an MSF HIV/TB advisor based in South Africa. “With no HIV vaccine or cure in sight, CAB-LA and other long-acting formulations can be a gamechanger in curbing the HIV epidemic if scaled up globally, especially in low- and middle-income countries, particularly among groups at higher risk of acquiring HIV.”
In Africa, four countries started offering CAB-LA in 2024: Zimbabwe, Malawi, Zambia, and eSwatini. South Africa is scheduled to receive a portion of the 231,000 doses of CAB-LA from the President's Emergency Plan for AIDS Relief (PEPFAR) before the end of the year. The remaining PEPFAR doses will be released over the next two years. After long negotiations with ViiV, the sole manufacturer of CAB-LA, MSF successfully secured a limited number of doses, which are expected to be administered in its projects in Zimbabwe, Mozambique, Malawi, and eSwatini later this year.
CAB-LA is more discreet than the once-daily oral PrEP pill and could encourage adherence to this form of prevention. Discretion can be especially important for key and vulnerable populations at risk of HIV, like girls and women, sex workers, and men who have sex with men. Another long-acting option, lenacapavir made by Gilead, can be administered every six months and is expected to expand prevention choices in the coming years.